Similarly, a randomized phase III trial conducted by the Children’s Oncology Group (COG) showed that the combination of anti-GD2 ch14.18 (dinutuximab) with GM-CSF and IL-2 could improve survival rates among children with high-risk neuroblastoma [177]. Here, IL2 is linked to neuroblastoma.